Cybin Inc. (CYBN)

NYSEAMERICAN: CYBN · Real-Time Price · USD

9.09

-0.24 (-2.57%)

At close: Feb 21, 2025, 4:00 PM

9.01

-0.08 (-0.88%)

After-hours: Feb 21, 2025, 7:58 PM EST

Cybin Employees

Cybin had 50 employees as of March 31, 2024. The number of employees did not change compared to the previous year.

Employees

50

Change (1Y)

n/a

Growth (1Y)

n/a

Revenue / Employee

n/a

Profits / Employee

-$1,444,275

Market Cap

191.22M

Employees Chart

Employees History

Date	Employees	Change	Growth
Mar 31, 2024	50	0	-
Mar 31, 2023	50	0	-
Mar 31, 2022	50	12	31.58%
Mar 31, 2021	38	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	440,000
Johnson & Johnson	131,900
Thermo Fisher Scientific	122,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	72,000

Employee Rankings

CYBN News

11 days ago - Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights - Business Wire
5 weeks ago - Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder - Business Wire
5 weeks ago - Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025 - Business Wire
6 weeks ago - Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 - Business Wire
2 months ago - Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results - Business Wire
2 months ago - Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024 - Business Wire
3 months ago - Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder - Business Wire
3 months ago - Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024 - Business Wire